GESSEL is providing legal support to Pure Biologics S.A. as it prepares a new issue of shares and a shift of its shares from the NewConnect alternative trading system to the main floor of the Warsaw Stock Exchange. Before embarking on the share issue proper, the company worked with GESSEL on a number of preparatory tasks, including due diligence and revision of certain documents; we also represented the issuer as it sought approval for the issue prospectus from the Polish Financial Supervision Authority. The share offer is being coordinated by Dom Maklerski BOŚ.

Pure Biologics S.A. plans to apply proceeds from the issue towards further development, financing ongoing R&D work as well as commencing new studies of potential oncological and immunological therapies.

Our firm’s team working on this project was led by Krzysztof Marczuk, partner and included Magdalena Szeplikmanaging associateDawid Marciniak, associate and Urszula Śleszycka, associate.

Pure Biologics S.A. is a Wrocław-based biotech company focusing on antibody-based treatments and on new extracorporal therapies employing aptameres. These various projects build on the possibilities offered by molecular biology in treating autoimmune, oncological, and neurological conditions, some of them very rare ones.